Traders should prepare for potential volatility following the March 30 earnings release, particularly around pipeline progress, cash runway, and R&D spend. Monitor for updates on clinical trial timelines and funding needs.
NMRA drugs
NMRA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 16 $2.87entry
- T+1 · 8mo ago −1.39%α −1.67% · $2.83
- T+5 · 8mo ago −13.94%α −11.90% · $2.47
- T+20 · 7mo ago −29.27%α −33.05% · $2.03
- T+60 · 5mo ago −43.55%α −54.04% · $1.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Neumora Therapeutics announced it will report its Q4 and full-year 2025 financial results on March 30, 2026, via a live webcast and conference call. No financial data was released in this announcement, it is solely a press release notifying investors of an upcoming earnings event.
Key Facts
- Neumora Therapeutics will report Q4 and full-year 2025 financial results on March 30, 2026.
- Event will include a conference call and live webcast at 8:00 a.m. ET.
- No financial results or business updates were disclosed in this press release.
- Replay will be available on the company's website for up to 30 days.
Financial Impact
No financial data disclosed, impact to be determined at earnings release.
Risk Factors
- Biotech earnings can be volatile, especially for clinical-stage companies with no revenue.
- Potential for dilutive financing if cash runway is short and no partnerships are announced.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256107 |
Track record
14 reports on NMRA
3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
- Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
- Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
- Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
- Aug 17, 202613w ago 144 Bearish 5/10 Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
- Aug 14, 202613w ago 8-K Neutral 4/10 No price data
- Aug 14, 202613w ago Press Release Neutral 4/10 Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
- Jul 27, 202616w ago 8-K Bullish 5/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
- Jul 27, 202616w ago Press Release Bullish 7/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers